Pliant reports Q2 2026 results, adds two oncology-focused directors as FORTIFY enrollment continuesAug 11Quarterly updatePliant Therapeutics, Inc.PLN-101095
Pliant's BEACON-IPF trial terminated after DSMB recommendation; results postedAug 5Trial updatePliant Therapeutics, Inc.PLN-74809
Pliant Therapeutics expands board, adds two independent directorsJul 13PeoplePliant Therapeutics, Inc.
Sign in